A PHASE 1, SINGLE ASCENDING DOSE (SAD) STUDY OF FOOD EFFECT AND DRUG-DRUG INTERACTION (DDI) EFFECTS OF PH-MODIFYING AGENTS ON INCB099280 PHARMACOKINETICS (PK), A PROGRAMMED DEATH-LIGAND 1 (PD-L1) INHIBITOR, IN HEALTHY PARTICIPANTS

被引：0

|

作者：

Gong, X. ^{[1
]}

Cimino, E. ^{[1
]}

Leonetti-Whalen, C. ^{[1
]}

Wang, P. ^{[1
]}

Chen, X. ^{[1
]}

Punwani, N. ^{[1
]}

机构：

[1] Incyte Res Inst, Wilmington, DE USA

来源：

CLINICAL PHARMACOLOGY & THERAPEUTICS | 2024年 / 115卷

关键词：

D O I：

暂无

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

PII-094

引用

收藏

页码：S79 / S79

页数：1

相关论文

共 3 条

[1] A PHASE 1 SINGLE ASCENDING DOSE (SAD) STUDY OF FOOD EFFECTS AND DRUG-DRUG INTERACTION (DDI) EFFECTS OF PH-MODIFYING AGENTS ON INCB099318 PHARMACOKINETICS (PK), A PROGRAMMED DEATH-LIGAND 1 (PD-L1) INHIBITOR, IN HEALTHY PARTICIPANTS
Gong, X.
Xun, Z.
Leonetti-Whalen, C.
Wang, P.
Chen, X.
Punwani, N.
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2024, 115 : S78 - S78
[2] A phase 1 study of the small-molecule PD-L1 inhibitor INCB099280 in select advanced solid tumors: Updated safety, efficacy, and pharmacokinetics (PK) results
Prenen, Hans
Daniel, Jeannie
Ebiana, Victoria
Howe, Jason
Gong, Xiaohua
Spitz, Susan
Italiano, Antoine
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[3] A PHASE 1 DRUG-DRUG INTERACTION STUDY ASSESSING THE EFFECTS OF STEADY STATE (SS) PROBENECID (PB) ON SINGLE-DOSE BEMPEDOIC ACID (BA) PHARMACOKINETICS (PK) IN HEALTHY SUBJECTS.
Emery, M.
Hanselman, J.
MacDougall, D.
Amore, B.
Sasiela, W.
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2020, 107 : S43 - S43